Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells
T Nomura, M Yamasaki, Y Nomura… - Oncology …, 2005 - spandidos-publications.com
Acquired multi-drug resistance remains a major obstacle in the management of prostate
cancer. The objective of this study was to examine whether chemoresistance could be due in …
cancer. The objective of this study was to examine whether chemoresistance could be due in …
Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells
M Yamasaki, T Nomura, F Sato… - Oncology …, 2007 - spandidos-publications.com
Tumor hypoxia is a common feature of several cancers, including prostate cancer, and is
associated with tumor progression, acquisition of anti-apoptotic potential and therapeutic …
associated with tumor progression, acquisition of anti-apoptotic potential and therapeutic …
[HTML][HTML] Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer
…, T Matsubara, K Hirai, M Yamasaki… - Oncology …, 2014 - spandidos-publications.com
Heat shock proteins (HSPs), which are molecular chaperones that stabilize numerous vital
proteins, may be attractive targets for cancer therapy. The aim of the present study was to …
proteins, may be attractive targets for cancer therapy. The aim of the present study was to …
Chronic hypoxia induces androgen-independent and invasive behavior in LNCaP human prostate cancer cells
M Yamasaki, T Nomura, F Sato, H Mimata - Urologic Oncology: Seminars …, 2013 - Elsevier
Purpose Tumor hypoxia is a common feature of any cancer, including prostate cancer (CaP),
and associated with tumor cell aggressiveness. Although some reports are available on …
and associated with tumor cell aggressiveness. Although some reports are available on …
[HTML][HTML] Hypoxia-induced angiopoietin-like protein 4 as a clinical biomarker and treatment target for human prostate cancer
…, K Iwasaki, R Sato, M Yamasaki… - Oncology …, 2017 - spandidos-publications.com
Angiopoietin-like protein 4 (ANGPTL4) is a multifunctional protein, playing roles in glucose
and lipid metabolism, inflammation, angiogenesis, and tumorigenesis. Recent research …
and lipid metabolism, inflammation, angiogenesis, and tumorigenesis. Recent research …
[HTML][HTML] Angiopoietin-like protein 2 induces androgen-independent and malignant behavior in human prostate cancer cells
R Sato, M Yamasaki, K Hirai… - Oncology …, 2015 - spandidos-publications.com
Angiopoietin-like proteins (ANGPTLs), which comprise 7 members (ANGPTL1-ANGPTL7),
structurally resemble angiopoietins. We investigated the roles of ANGPTLs in the acquisition …
structurally resemble angiopoietins. We investigated the roles of ANGPTLs in the acquisition …
[HTML][HTML] Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer …
T Nomura, M Yamasaki, K Hirai, T Inoue, R Sato… - Molecular Cancer, 2013 - Springer
Background The Vav family of Rho/Rac guanosine nucleotide exchange factors comprises
three members in mammalian cells. Vav3 enhances androgen receptor (AR) activity during …
three members in mammalian cells. Vav3 enhances androgen receptor (AR) activity during …
Lower incidence of inguinal hernia: minilaparotomy radical retropubic prostatectomy compared with conventional technique: a preliminary report
…, H Kitamura, Y Fujikura, Y Akita, M Yamasaki… - Urologia …, 2005 - karger.com
Introduction: The purpose of the present study was to compare the incidence of inguinal
hernias after conventional and minilaparotomy (minilap) radical retropubic prostatectomy (RRP). …
hernias after conventional and minilaparotomy (minilap) radical retropubic prostatectomy (RRP). …
[HTML][HTML] Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
M Yamasaki, T Yuasa, S Uehara, Y Fujii… - International journal of …, 2016 - Springer
Background In order to help in selecting the optimum bone-modifying agent (BMA; zoledronic
acid or denosumab), we investigated the impact of the BMA on the renal function of …
acid or denosumab), we investigated the impact of the BMA on the renal function of …
Efficacy and safety profile of enzalutamide for Japanese patients with castration-resistant prostate cancer
M Yamasaki, T Yuasa, S Yamamoto… - Anticancer …, 2016 - ar.iiarjournals.org
Enzalutamide is a novel, non-steroidal anti-androgen that was approved for the treatment of
patients with castration-resistant prostate cancer (CRPC) in 2014 in Japan. To assess the …
patients with castration-resistant prostate cancer (CRPC) in 2014 in Japan. To assess the …